Sr. Vice Pres., CFO Tokich Michael J exercised 23,332 units of Ordinary Shares at a strike of $114.22 and sold $5,714,643 worth of Ordinary Shares (23,332 units at $244.93) (SEC Form 4)
$STE
Industrial Specialties
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
|
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | ||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 09/13/2024 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Ordinary Shares | 09/13/2024 | M | 3,119 | A | $114.22 | 46,049 | D | |||
| Ordinary Shares | 09/13/2024 | S | 3,119 | D | $248.02(1) | 42,930 | D | |||
| Ordinary Shares | 09/16/2024 | M | 20,213 | A | $114.22 | 63,143 | D | |||
| Ordinary Shares | 09/16/2024 | S | 10,316 | D | $243.53(2) | 52,827 | D | |||
| Ordinary Shares | 09/16/2024 | S | 3,485 | D | $244.55(3) | 49,342 | D | |||
| Ordinary Shares | 09/16/2024 | S | 5,985 | D | $245.79(4) | 43,357 | D | |||
| Ordinary Shares | 09/16/2024 | S | 427 | D | $247.08(5) | 42,930 | D | |||
| Ordinary Shares | 3,566 | I | See Footnote Below(6) | |||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Employee Stock Option (right to buy) | $114.22 | 09/13/2024 | M | 3,119 | (7) | 05/31/2028 | Ordinary Shares | 3,119 | $0 | 20,213 | D | ||||
| Employee Stock Option (right to buy) | $114.22 | 09/16/2024 | M | 20,213 | (7) | 05/31/2028 | Ordinary Shares | 20,213 | $0 | 0 | D | ||||
| Explanation of Responses: |
| 1. Price reflects a weighted average sale price for multiple transactions ranging from $248.00 to $248.08 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 2. Price reflects a weighted average sale price for multiple transactions ranging from $243.08 to $244.07 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 3. Price reflects a weighted average sale price for multiple transactions ranging from $244.14 to $245.105 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 4. Price reflects a weighted average sale price for multiple transactions ranging from $245.43 to $246.405 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 5. Price reflects a weighted average sale price for multiple transactions ranging from $246.4675 to $247.44 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 6. Units representing 3,566 ordinary share equivalents are held on behalf of the Reporting Person under the STERIS Corporation 401(k) Plan as of September 10, 2024. |
| 7. This option to purchase 46,664 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 46,664 ordinary shares for $114.22 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option. |
| Remarks: |
| /s/ John P. Ubbing, Authorized Representative under Power of Attorney | 09/17/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||